Clinical Trial Detail

NCT ID NCT02477696
Title Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

chronic lymphocytic leukemia

Therapies

Acalabrutinib

Ibrutinib

Age Groups: adult

No variant requirements are available.